HeimBIIB • NASDAQ
add
Biogen Inc
153,43 $
Eftir lokun(0,098%)-0,15
153,28 $
Lokað: 5. nóv., 16:40:39 GMT-5 · USD · NASDAQ · Lagalegir fyrirvarar
Við síðustu lokun
149,33 $
Dagbil
148,51 $ - 153,68 $
Árabil
110,04 $ - 179,20 $
Markaðsvirði
22,51 ma. USD
Meðalmagn
1,72 m.
V/H-hlutf.
13,99
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 2,53 ma. | 2,79% |
Rekstrarkostnaður | 1,25 ma. | -1,34% |
Nettótekjur | 466,50 m. | 20,08% |
Hagnaðarhlutfall | 18,40 | 16,75% |
Hagnaður á hvern hlut | 4,81 | 17,89% |
EBITDA | 980,80 m. | 23,54% |
Virkt skatthlutfall | 16,29% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 3,96 ma. | 133,07% |
Heildareignir | 29,21 ma. | 3,16% |
Heildarskuldir | 11,00 ma. | -7,98% |
Eigið fé alls | 18,21 ma. | — |
Útistandandi hlutabréf | 146,70 m. | — |
Eiginfjárgengi | 1,20 | — |
Arðsemi eigna | 6,77% | — |
Ávöxtun eigin fjár | 7,94% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 466,50 m. | 20,08% |
Handbært fé frá rekstri | 1,27 ma. | 36,01% |
Reiðufé frá fjárfestingum | -35,10 m. | 97,03% |
Reiðufé frá fjármögnun | -130,20 m. | -1.872,73% |
Breyting á handbæru fé | 1,10 ma. | 626,47% |
Frjálst peningaflæði | 1,01 ma. | -12,12% |
Um
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Framkvæmdastjóri
Stofnsett
1978
Höfuðstöðvar
Vefsvæði
Starfsfólk
7.605
